FDA Brief

Warning letters Drugs

FDA warning letter to

System Kosmetik Produktionsgesellschaft fur kosmetische Gmbh

High riskIssued Sep 9, 2022Posted Sep 27, 2022Center for Drug Evaluation and Research | CDER

German OTC drug maker System Kosmetik was cited for manufacturing quality violations, including missing process and cleaning validation.

What happened

FDA inspected the facility from February 16 to February 18, 2022. FDA found no data validating OTC drug manufacturing processes, batch records missing critical production details, drug products made on equipment shared with non-pharmaceutical products without adequate cleaning validation, and microbial testing results above U.S. Pharmacopeia (USP) limits. FDA also found no identity testing of incoming active ingredients and FTIR computer controls that lacked unique usernames/passwords and had the audit trail disabled.

What FDA found

  1. The company lacked adequate written production and process control procedures and had no data to show its OTC drug manufacturing processes were validated.

    21 CFR 211.100(a)
  2. The company made OTC drugs on equipment also used for non-pharmaceutical products and did not have sufficient cleaning validation for the shared equipment.

    21 CFR 211.67(b)
  3. The company's laboratory controls were inadequate, with microbial testing results above USP criteria and missing specifications or testing for certain items.

    21 CFR 211.160(b)
  4. The company released active pharmaceutical ingredients without testing each lot to verify identity.

    21 CFR 211.84(d)(1)
  5. The company's FTIR system lacked unique usernames and passwords, and its audit trail was disabled.

    21 CFR 211.68(b)

What FDA wants

FDA asks the company to respond in writing within 15 working days with corrective actions and detailed remediation plans, including process and cleaning validation, risk assessments, API identity testing, and a data integrity investigation.

Who should pay attention

  • U.S. importers and distributors of OTC drugs from this facility
  • brands that buy OTC drugs from this manufacturer
  • companies that share drug and non-drug equipment

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk